Jefferies Group’s AnaptysBio ANAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-30,000
Closed -$647K 1641
2021
Q1
$647K Buy
30,000
+6,800
+29% +$172K 0.01% 1048
2020
Q4
$499K Hold
23,200
﹤0.01% 1135
2020
Q3
$342K Buy
+23,200
New +$419K ﹤0.01% 1070
2018
Q4
Sell
-3,400
Closed -$339K 2136
2018
Q3
$339K Buy
+3,400
New +$282K ﹤0.01% 1817

Other funds holding ANAB

Jefferies Group's ANAB Position: Q2 2021 in Review

Jefferies Group sold out of AnaptysBio (ANAB) in Q2 2021, closing a stake of 5,710 shares — an estimated $123K sold.

Jefferies Group first reported a position in ANAB in Q3 2019 and held it in 5 quarters. The position peaked at $488K in Q4 2019. 122 funds tracked by Wall St. Rank hold ANAB as of Q2 2021.

  • Jefferies Group reported no remaining AnaptysBio position as of Q2 2021 after selling out during the quarter.
  • Jefferies Group sold 5,710 AnaptysBio shares in Q2 2021, an estimated $123K.
  • Jefferies Group first reported a position in AnaptysBio in Q3 2019 and held it in 5 quarters.
  • Jefferies Group's AnaptysBio position peaked at $488K in Q4 2019.
  • 122 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2021.

Based on Jefferies Group's 13F filing for Q2 2021, filed 16 Aug 2021.